



1st International Electronic Conference on Medicinal Chemistry

2-27 November 2015

chaired by Dr. Jean Jacques Vanden Eynde

sponsored by



pharmaceuticals

Synthesis of aminated xanthenes: exploiting chemical routes to reach for bioactive compounds

Emília Sousa ^{1,2,*}, Agostinho Lemos ¹, Ana Gomes ^{1,3}, Sara Cravo ¹, Madalena Pinto ^{1,2}

¹ Department of Chemical Sciences, Laboratory of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Porto, Portugal;

² CIIMAR – Interdisciplinary Centre of Marine and Environmental Research, Portugal;


² Department of Biological Sciences, Laboratory of Microbiology, Faculty of Pharmacy, University of Porto, Portugal.



* Corresponding author: esousa@ff.up.pt

Synthesis of aminated xanthenes: exploiting chemical routes to reach for bioactive compounds

Graphical Abstract



Abstract:

Typically, about 90% of drug candidates are N-containing, and an even higher amount are O-containing. As a consequence, it is not surprising that alkylation and arylation of groups with nitrogen and oxygen emerge as major reactions to obtain bioactive compounds. Xanthenes are a class of O-heterocycles characterized by a dibenzo- γ -pyrone nucleus. This scaffold may be considered a “privileged structure” able of providing useful ligands for several types of receptors and/or enzymes targets by judicious structural modifications. In our search for potential anticancer drugs we pursuit with a hybridization approach of N-containing xanthenes.


Herein, exploiting chemical routes to reach for bioactive N-containing xanthenes with will be shared. The synthesis of new xanthone derivatives proceeds by both strategies and the respective strengths and weakness will be presented in a “medchem” perspective. Although chemical route (i) (SN2 reactions and nucleophilic aromatic substitutions) provided interesting antitumor derivatives, the reductive amination (ii) furnished a library of potential p53:MDM2 inhibitors with noticeable advantages such as: high-yield reactions, one-pot conversions, aliphatic amines with low potential to form reactive metabolites.

The use of a variety of (thio)xanthone building blocks, with various substituents, and different reaction conditions allowed us to develop a repertoire of N-transformations.

Keywords: Ullmann Coupling; Reductive Amination; Xanthenes; Bioactive compounds



Introduction



Top 10 Reactions *

reaction	no. of reactions	% of all reactions
N-acylation to amide	1165	16.0
N-containing heterocycle formation	537	7.4
N-arylation with Ar-X	458	6.3
RCO ₂ H deprotection	395	5.4
N-subs with alkyl-X	390	5.3
reductive amination	386	5.3
N-Boc deprotection	357	4.9
Suzuki cross-coupling reaction	338	4.6
O-substitution	319	4.4
other NH deprotection	212	2.9
total	4557	62.4

*by Frequency in the 2008 Data Set, J. Med. Chem. 2011, 54, 3451–3479



1st International Electronic Conference
on Medicinal Chemistry
2-27 November 2015


sponsors:



pharmaceuticals

Common approach of most medicinal chemistry programs


- synthesizing a common core motif
- performing multiple derivatizations of this core



Dibenzo-gamma-pirone

Pedro, M. M.; Cerqueira, F.; Sousa, M. E.; Nascimento, M. S. J.;
Pinto, M. M. M. *Bioorg. Med. Chem.* 2002, 10, 3725–3730.

useful structure-activity relationships (SAR)



R1	R2	R3	R4	R5
OH	H	H	H	H
H	OH	H	H	H
H	H	OH	H	H
H	H	H	OH	H
OCH ₃	H	H	H	H
H	OCH ₃	H	H	H
H	H	OCH ₃	H	H
H	H	H	OCH ₃	H
OH	OH	H	H	H
H	OH	OH	H	H
H	H	OH	OH	H
H	H	OCH ₃	OH	H
H	H	OH	OCH ₃	H
H	H	OH	H	OH
H	H	OCH ₃	H	OCH ₃
H	H	OCH ₃	H	OH
OH	CH ₃	OH	H	H
H	OH	OH	OCH ₃	H
CHO	H	OCH ₃	OH	H
H	CHO	OH	OCH ₃	H



1st International Electronic Conference
on Medicinal Chemistry
2-27 November 2015


sponsors:





pharmaceuticals

Two projects of hit-to-lead optimization


1. Optimization of an antitumor thioxanthone



lucanthone




1-chloro-4-propoxy-9H-thioxanthen-9-one



development of P-glycoprotein inhibitors with antitumor activity

2. Optimization of a potent inhibitor of p53-MDM2 interaction




LEM2



cis-Imidazoline
Morpholinone
Piperidinone
Pyrrolidine
Quinolinol



Classes of known p53:MDM2 inhibitors




development of hybrids



1. N-Arylation with Ar-X



~ 1000 designed
thioxanthenes (Tx)




-
- LogP
 - MW
 - Amine

P-glycoprotein


Molecules with
the best
scores

Hundreds...
















Docking


1. N-Arylation with Ar-X




a) Cu_2O , MeOH,
100°C closed vessel,
2 days




1. N-Arylation with Ar-X




a) Cu_2O , MeOH, 100°C closed vessel, 2 days




b) Cu_2O , K_2CO_3 , MeOH closed vessel, 100°C , 2 days




c) Cu_2O , K_2CO_3 , NMP, MW 205°C , 50 min




1. N-Arylation with Ar-X



Results and discussion




Catalyst	Amount of catalyst	Ligand	Base	Solvent	Yield (HPLC)	
					TXA1	TXOMe
Cu ₂ O	5% mol		K ₂ CO ₃	Methanol	trace	
Cu(0)	5% mol		K ₂ CO ₃	Methanol	trace	
CuI	5% mol		K ₂ CO ₃	Methanol	26	1
CuI	10% mol		K ₂ CO ₃	Methanol	55	11
CuI	5% mol		K ₂ CO ₃	Acetonitrile	trace	
CuI	5% mol		K ₂ CO ₃	Isopropanol	trace	
CuI	5% mol		K ₂ CO ₃	Propanol	trace	
CuI	5% mol		K ₂ CO ₃	NMP	trace	
CuI	5% mol		K ₂ CO ₃	Water	trace	
CuI	5% mol		K ₂ CO ₃	Ethanol	12	2 (TXOEt)
CuI	5% mol		K ₂ CO ₃	Formamide	trace	
CuI	5% mol		K ₂ CO ₃	neat	trace	
CuI	5% mol		Et₃N	neat	trace	
CuI	5% mol		K ₂ CO ₃	Ethylenoglycol	10	
Pd(dppf)Cl₂·CH₂Cl₂	5% mol		K ₂ CO ₃	Methanol	trace	
Pd₂(dba)₃·BINAP	5% mol		tBuONa	Methanol	trace	n.d.
Pd₂(dba)₃ : BINAP	5% mol		CsCO₃	Methanol	trace	
CuI	5% mol	Picolinic acid 20% mol	K ₂ CO ₃	Methanol	trace	
CuI	5% mol	N,N-dimethylglycine 20% mol	K ₂ CO ₃	Methanol	43	4
CuI	5% mol	N,N-dimethylglycine 20% mol	K ₂ CO ₃	neat	9	
CuI	5% mol	N,N-dimethylglycine 20% mol	K ₂ CO ₃	Ethylenoglycol	trace	
CuI + Montmorillonite K10	5% mol + 10eq		K ₂ CO ₃	Methanol	16	n.d.



50% overall yield (~10g)

Buchwald-Hartwig reaction

1. N-Arylation with Ar-X





- Widespread commercial **availability halogenated** heterocyclic moieties precursor (one-pot reactions)
- **Catalysis and microwave-** assisted chemistry (CuI/*N,N*-dimethylglycine is a cheap and efficient catalytic system)
- Strategy in obtaining directly **hydrochlorides** fruitful

- Difficulty of coupling electron-rich and **low reactive** aryl chlorides and hindered, **unreactive** amine substrates (low-yield reactions)
- Only vanishingly small levels of **residual alkylating** agents and **metals** should be present in drug candidates
- **N-aromatics risks of metabolizing to anilines**



2. Optimization of a potent inhibitor of p53-MDM2 interaction

- ❖ Xanthone derivatives represent a privileged scaffold for antitumor agents with the ability to activate p53 pathway



M. Leão, et al. Biochemical Pharmacology 2013, 85(9), 1234-1245.
M. Leão, et al. Journal of Natural Products 2013, 76 (4), 774-778.




1st International Electronic Conference
on Medicinal Chemistry
2-27 November 2015

sponsors:




pharmaceuticals


Reductive Amination




Obtaining the functionalized aldehyde was the 1st drawback for a rapid synthetic protocol





Reductive Amination



Obtaining the functionalized aldehyde was the 1st drawback for a rapid synthetic protocol



Reductive Amination



LEM2

Table 1. Reaction yields (%) of the new aminoxanthone derivatives*

- a) MP-CNBH₃, CH₃COOH, CH₃OH, r.t., overnight
 b) STAB, CH₃COOH, THF, r.t., overnight

LEM2	Compounds	Yield (%)	Compounds	Yield (%)	Compounds	Yield (%)
	ALX1	56	ALX5	40	ALX9	35
	ALX2	57	ALX6	63	ALX10	36
	ALX3	70	ALX7	68	ALX11	58
	ALX4	41	ALX8	62		

MP-CNBH₃ = Solid-supported cyanoborohydride, STAB = Sodium triacetoxyborohydride, THF = tetrahydrofuran, r.t. = room temperature

*Due to confidentiality issues, the compounds are not shown.



1st International Electronic Conference
 on Medicinal Chemistry
 2-27 November 2015

sponsors:



pharmaceuticals

Reductive Amination



- **high-yield** reactions (the intermediate imine does not suffer from the issues of over-reaction)
- **metal-free** reactions
- aliphatic amines with **low potential to form reactive metabolites**


- **Preparation of aldehyde** heterocyclic moieties precursors difficult /restrains availability than halogenated precursors
- highly **sensitive to solvent/reagents** modifications



Conclusions

a variety of (thio)xanthone building blocks, pendent functionalities, and different reaction conditions allowed us to develop a repertoire of *N*-transformations

Importance the use of enabling techniques in synthesis



Microwave irradiation

New solvents

Catalysis



Acknowledgments

national funds from FCT—Fundação para a Ciência e a Tecnologia under the project CEQUIMED—PEst-OE/SAU/UI4040/2014 and ERDF through COMPETE and national funds from FCT, PEst-C/MAR/LA0015/2013.

FCT Fundação para a Ciência e a Tecnologia

MINISTÉRIO DA CIÊNCIA, TECNOLOGIA E ENSINO SUPERIOR Portugal



1st International Electronic Conference
on Medicinal Chemistry
2-27 November 2015

sponsors:



pharmaceuticals